← Human Trials & Peer-Reviewed Studies
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
Plain-language guide to PMID 35659622 (2022): double-blind randomized controlled trial study of CGRP (Calcitonin Gene-Related Peptide), migraine.
Key Facts
- PMID
- 35659622
- Journal
- BMC neurology
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Ailani J et al. (9 authors)
- DOI
- 10.1186/s12883-022-02714-1
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of CGRP (Calcitonin Gene-Related Peptide) in the context of migraine, published as a randomized controlled trial.
Who Took Part
The age groups tagged for this paper are adults.
Outcome measures included headache pain freedom/relief and absence of MBS, patient's choice of photophobia, phonophobia, or nausea, at regular intervals from 0.5 to 48 h after infusion start.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.
The participants were allocated by chance, so the CGRP (Calcitonin Gene-Related Peptide) group and the comparison group should start out alike.
Neither the participants nor the staff measuring them knew who was on CGRP (Calcitonin Gene-Related Peptide), so expectations could not easily colour the readings.
Some participants received a placebo instead of CGRP (Calcitonin Gene-Related Peptide), giving a reference point.
Running at several centres spread the CGRP (Calcitonin Gene-Related Peptide) study over different clinics and patient groups.
RELIEF, a multicenter, parallel-group, double-blind trial, occurred from November 7, 2019, through July 8, 2020.
Censoring was applied at time of acute rescue medication use.
What Was Measured
Topics PubMed links to this paper include Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide, Headache, Hyperacusis, Migraine Disorders, Nausea and Photophobia.
The authors tagged it with the keywords CGRP, Eptinezumab and MBS.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of CGRP (Calcitonin Gene-Related Peptide) in people with migraine.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (BMC neurology), a journal based in England.
More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Migraine research.
Our Notes on the Compound
CGRP (Calcitonin Gene-Related Peptide): A 37-amino-acid neuropeptide that widens blood vessels and is involved in migraine; given in research provocation studies.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.